BEACON-1 trial (AVZO-103): what clinicians have said so far
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
- NCT07193511 ↗
- Recruiting
- Avenzo Therapeutics, Inc.
- Focused size, estimated: 1–150 verified statements once built
Discussed at: 2026 ASCO Genitourinary Cancers Symposium
We haven't built an HCP commentary report on BEACON-1 (AVZO-103 in locally advanced or metastatic solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on BEACON-1 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-103, a Nectin4/Trop2 ADC, as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Solid Tumor Cancer; Locally Advanced; Metastatic Solid Tumors; Urothelial Cancer
- Interventions
- AVZO-103; Combination Agent
- Arms
- Phase 1, monotherapy · Experimental
- Phase 1, combination · Experimental
- Phase 2, monotherapy · Experimental
- Phase 2, combination · Experimental
- Enrollment
- 355 (estimated)
- Primary outcomes
- Occurrence of Dose Limiting Toxicities (DLTs) during the first cycle (Phase 1)
- Determine the maximum tolerated dose (MTD) and/or preliminary recommended Phase 2 dose (RP2D) (Phase 1)
- Number of Participants with Treatment Emergent Adverse Events (TEAEs) and lab abnormalities (Phase 1)
- Objective Response Rate (ORR) (Phase 2)
- Sponsor
- Avenzo Therapeutics, Inc.
- Start
- Oct 2, 2025
- Primary completion
- Mar 2030 (estimated)
- Results posted
- No
- Registry record
- NCT07193511 · updated Oct 5, 2026